Nørgaard-Pedersen B, Hangaard J
Clin Lab Med. 1982 Sep;2(3):431-58.
This article only presents some of the important aspects of GCT pathology, management, and tumor markers. Several essential research areas have not been included. Experimental models, such as animal models, tissue culture lines, and heterotransplantation have been described elsewhere. This is also true for radioimmune detection and for "carcinoma in situ" of the testis. Germ cell tumors are unique since, to a large extent, they are curable. In contrast to the painstakingly slow progress in the treatment of other solid tumors, new radiotherapy and chemotherapy regimens and better monitoring have drastically altered survival in patients with germ cell tumors. However, many questions remain unanswered. Are some patients being overtreated, and can treatment regimens be minimized? Can patients at risk for recurrence be more accurately identified, and should treatment be more aggressive in such cases? To answer these questions it will be necessary to carry out large prospective, randomized trials both at the national and international level. To achieve progress in GCT research it is also important to continue the interdisciplinary approach, which has proven so fruitful not only for patients with germ cell tumors but also for cancer research in general.
本文仅介绍了生殖细胞肿瘤病理学、治疗及肿瘤标志物的一些重要方面。一些关键研究领域未被涵盖。实验模型,如动物模型、组织培养系和异种移植,已在其他地方有所描述。睾丸的放射免疫检测及“原位癌”情况亦是如此。生殖细胞肿瘤很独特,因为在很大程度上它们是可治愈的。与其他实体瘤治疗进展极为缓慢形成对比的是,新的放疗和化疗方案以及更好的监测手段已极大地改变了生殖细胞肿瘤患者的生存率。然而,许多问题仍未得到解答。是否有患者接受了过度治疗,治疗方案能否简化?能否更准确地识别复发风险患者,在此类情况下治疗是否应更积极?要回答这些问题,有必要在国家和国际层面开展大型前瞻性随机试验。为推动生殖细胞肿瘤研究取得进展,继续采用跨学科方法也很重要,事实证明,这一方法不仅对生殖细胞肿瘤患者,而且对整个癌症研究都成效显著。